Clinical and Medical Affairs · Medical Devices

Clinical and Medical Affairs for Medical Devices.

Regenesis Scientific Strategy provides specialized Clinical and Medical Affairs strategy for medical device companies. Structured plans, current literature, and trial analytics — from first evidence plan through commercial launch.

The vision is that a medical device company can hire Regenesis Scientific Strategy for the whole development path — not a separate vendor for every function. You work with us. We coordinate the rest.

Scientists reviewing brain imaging and a protocol together in a quiet research suite.

30 years

Scientific strategy — from research through regulatory labeling.

20 years

Medical device Clinical and Medical Affairs.

Class I–III

Class I, II, and III device programs.

50+ trials

30+ sponsors

First-in-human to post-market.

01Work

Recent engagements

Clients

What sponsors take away.

“We asked Regenesis Scientific Strategy to help us take the IDE study design to the American Headache Society Annual Scientific Meeting, the main scientific meeting for our migraine program. They worked closely with our key HCPs and internal teams, tightened the scientific communications strategy, and drafted the late-breaking abstract and poster. Late-breaking is a short window and a harder review than the regular program — and it was accepted.

In parallel, Regenesis partnered with us to analyze data and evaluate programming activities and clinical outcomes. Their work provided valuable insights that supported our programming approach for our IDE study. The result was a stronger scientific presence at AHS and a more informed perspective on our study data and clinical program.

That’s Clinical and Medical Affairs strategy, done well.”

Roni Diaz

VP, Clinical and Regulatory, Salvia BioElectronics

“Stephanie helped us build out clinical function and managed the 36-patient study we ran in-house for Opioid Addiction. She took us from FDA Pre-Submission through a successful clearance. When I hear of a company needing clinical and medical affairs leadership, I send them to Regenesis Scientific Strategy.”

Daniel Powell

Founder, Spark Biomedical

“Regenesis Scientific Strategy has been a valuable partner as we prepared for our FDA Pre-Sub. They helped align our team around the clinical evidence strategy, provided the framework and initial drafts for our Clinical Evidence Strategy Plan and CIP synopsis, and connected us with a variety of top-tier service providers including the biostatistical expertise needed to strengthen the study design.

Their experience helped us translate our clinical objectives into a clear, executable study plan and a well-structured package for FDA review.”

Jordan Doles

Founder and CEO, NeuroX Innovations

03How we work

The scientific question first. Then the plan.

Most device companies have a prototype and a claim, and not yet a clinical plan FDA or a notified body can use. We write the plan so the team is working from one document, keep the literature current, and review the data while the study is still running. We stay on the sponsor side, and Medical Affairs and scientific communications continue through launch.

  1. 01

    The question

    A 15- to 30-minute call to see whether there is a defined clinical or Medical Affairs need. If there is, a longer conversation follows, then a written proposal. You can adjust the scope until both sides agree.

  2. 02

    The plan

    Intended use, the claims the data can support, and a protocol synopsis before a study is contracted. Written so the team and the execution partner are working from the same synopsis. Small studies we can run. Larger studies we help you select the organization that will run the trial, and we manage it for the company so it is not handed off.

  3. 03

    The fee

    Fractional, project-based, or hourly — whichever fits the company and the work. The fee is agreed in writing before we start.

04Services

Clinical and Medical Affairs services.

Two colleagues working a clinical strategy over a brain atlas and protocol papers.

In short

Clinical and Medical Affairs strategy from first evidence plan through commercial launch.

Regenesis Scientific Strategy

The Regenesis Review

Subscribe if you want occasional Clinical and Medical Affairs insights.

We will not spam you, and you can leave anytime.

Read Issue 01

Contact

If you need Clinical and Medical Affairs strategy, get in touch.

A 15- to 30-minute call is enough to see whether we are a fit.

Contact us